• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺导管腺癌进展的动态分子网络分析

Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression.

作者信息

Pan Zongfu, Li Lu, Fang Qilu, Zhang Yiwen, Hu Xiaoping, Qian Yangyang, Huang Ping

机构信息

1Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, 310022 China.

2Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003 China.

出版信息

Cancer Cell Int. 2018 Dec 22;18:214. doi: 10.1186/s12935-018-0718-5. eCollection 2018.

DOI:10.1186/s12935-018-0718-5
PMID:30598639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6303882/
Abstract

BACKGROUND

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors. The rapid progression of PDAC results in an advanced stage of patients when diagnosed. However, the dynamic molecular mechanism underlying PDAC progression remains far from clear.

METHODS

The microarray GSE62165 containing PDAC staging samples was obtained from Gene Expression Omnibus and the differentially expressed genes (DEGs) between normal tissue and PDAC of different stages were profiled using R software, respectively. The software program Short Time-series Expression Miner was applied to cluster, compare, and visualize gene expression differences between PDAC stages. Then, function annotation and pathway enrichment of DEGs were conducted by Database for Annotation Visualization and Integrated Discovery. Further, the Cytoscape plugin DyNetViewer was applied to construct the dynamic protein-protein interaction networks and to analyze different topological variation of nodes and clusters over time. The phosphosite markers of stage-specific protein kinases were predicted by PhosphoSitePlus database. Moreover, survival analysis of candidate genes and pathways was performed by Kaplan-Meier plotter. Finally, candidate genes were validated by immunohistochemistry in PDAC tissues.

RESULTS

Compared with normal tissues, the total DEGs number for each PDAC stage were 994 (stage I), 967 (stage IIa), 965 (stage IIb), 1027 (stage III), 925 (stage IV), respectively. The stage-course gene expression analysis showed that 30 distinct expressional models were clustered. Kyoto Encyclopedia of Genes and Genomes analysis indicated that the up-regulated DEGs were commonly enriched in five fundamental pathways throughout five stages, including pathways in cancer, small cell lung cancer, ECM-receptor interaction, amoebiasis, focal adhesion. Except for amoebiasis, these pathways were associated with poor PDAC overall survival. Meanwhile, LAMA3, LAMB3, LAMC2, COL4A1 and FN1 were commonly shared by these five pathways and were unfavorable factors for prognosis. Furthermore, by constructing the stage-course dynamic protein interaction network, 45 functional molecular modules and 19 nodes were identified as featured regulators for all PDAC stages, among which the collagen family and integrins were considered as two main regulators for facilitating aggressive progression. Additionally, the clinical relevance analysis suggested that the stage IV featured nodes MLF1IP and ITGB4 were significantly correlated with shorter overall survival. Moreover, 15 stage-specific protein kinases were identified from the dynamic network and CHEK1 was particularly activated at stage IV. Experimental validation showed that MLF1IP, LAMA3 and LAMB3 were progressively increased from tumor initiation to progression.

CONCLUSIONS

Our study provided a view for a better understanding of the dynamic landscape of molecular interaction networks during PDAC progression and offered potential targets for therapeutic intervention.

摘要

背景

胰腺导管腺癌(PDAC)是最致命的实体瘤之一。PDAC的快速进展导致患者在确诊时已处于晚期。然而,PDAC进展背后的动态分子机制仍远未明确。

方法

从基因表达综合数据库获取包含PDAC分期样本的微阵列GSE62165,分别使用R软件分析不同阶段正常组织与PDAC之间的差异表达基因(DEG)。应用软件程序Short Time-series Expression Miner对PDAC各阶段之间的基因表达差异进行聚类、比较和可视化。然后,通过注释、可视化和综合发现数据库对DEG进行功能注释和通路富集分析。此外,应用Cytoscape插件DyNetViewer构建动态蛋白质-蛋白质相互作用网络,并分析节点和聚类随时间的不同拓扑变化。通过PhosphoSitePlus数据库预测阶段特异性蛋白激酶的磷酸化位点标记。此外,通过Kaplan-Meier绘图仪对候选基因和通路进行生存分析。最后,通过免疫组织化学在PDAC组织中验证候选基因。

结果

与正常组织相比,各PDAC阶段的DEG总数分别为994个(I期)、967个(IIa期)、965个(IIb期)、1027个(III期)、925个(IV期)。阶段过程基因表达分析显示聚类出30种不同的表达模型。京都基因与基因组百科全书分析表明,在五个阶段中,上调的DEG通常富集于五个基本通路,包括癌症通路、小细胞肺癌通路、细胞外基质-受体相互作用通路、阿米巴病通路、粘着斑通路。除阿米巴病通路外,这些通路均与PDAC总体生存率低相关。同时,这五个通路共同拥有LAMA3、LAMB3、LAMC2、COL4A1和FN1,且均为预后不良因素。此外,通过构建阶段过程动态蛋白质相互作用网络,鉴定出45个功能分子模块和19个节点作为所有PDAC阶段的特征性调节因子,其中胶原蛋白家族和整合素被认为是促进侵袭性进展的两个主要调节因子。此外,临床相关性分析表明,IV期特征性节点MLF1IP和ITGB4与较短的总生存期显著相关。此外,从动态网络中鉴定出15个阶段特异性蛋白激酶,CHEK1在IV期尤其被激活。实验验证表明,MLF1IP、LAMA3和LAMB3从肿瘤起始到进展逐渐增加。

结论

我们的研究为更好地理解PDAC进展过程中分子相互作用网络的动态格局提供了视角,并为治疗干预提供了潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/9a621bcd7bdf/12935_2018_718_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/850206269cb2/12935_2018_718_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/128b960c67ce/12935_2018_718_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/78f18d057370/12935_2018_718_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/82876e465f58/12935_2018_718_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/18e348413107/12935_2018_718_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/65b693eb78f3/12935_2018_718_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/858e3957ca83/12935_2018_718_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/e6921ecba648/12935_2018_718_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/0aefa7769c66/12935_2018_718_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/9a621bcd7bdf/12935_2018_718_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/850206269cb2/12935_2018_718_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/128b960c67ce/12935_2018_718_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/78f18d057370/12935_2018_718_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/82876e465f58/12935_2018_718_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/18e348413107/12935_2018_718_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/65b693eb78f3/12935_2018_718_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/858e3957ca83/12935_2018_718_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/e6921ecba648/12935_2018_718_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/0aefa7769c66/12935_2018_718_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c365/6303882/9a621bcd7bdf/12935_2018_718_Fig10_HTML.jpg

相似文献

1
Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression.胰腺导管腺癌进展的动态分子网络分析
Cancer Cell Int. 2018 Dec 22;18:214. doi: 10.1186/s12935-018-0718-5. eCollection 2018.
2
Identifying and as a potential combination of prognostic biomarkers in pancreatic ductal adenocarcinoma using integrated bioinformatics analysis.运用综合生物信息学分析鉴定 和 作为胰腺导管腺癌预后生物标志物的潜在组合。 (原文中“Identifying and”部分内容不完整,请确认准确信息后再让我翻译)
PeerJ. 2020 Nov 23;8:e10419. doi: 10.7717/peerj.10419. eCollection 2020.
3
ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis.整合生物信息学分析表明 ITGA2、LAMB3 和 LAMC2 可能是胰腺导管腺癌的潜在治疗靶点。
Sci Rep. 2021 May 18;11(1):10563. doi: 10.1038/s41598-021-90077-x.
4
Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues.胰腺导管腺癌及配对的相邻胰腺组织的综合转录组荟萃分析。
PeerJ. 2020 Oct 27;8:e10141. doi: 10.7717/peerj.10141. eCollection 2020.
5
Identification of potential target genes in pancreatic ductal adenocarcinoma by bioinformatics analysis.通过生物信息学分析鉴定胰腺导管腺癌中的潜在靶基因
Oncol Lett. 2018 Aug;16(2):2453-2461. doi: 10.3892/ol.2018.8912. Epub 2018 Jun 6.
6
Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.基于综合基因表达谱分析鉴定与胰腺导管腺癌相关的枢纽基因和调控因子
Discov Med. 2019 Sep;28(153):159-172.
7
Analysis of molecular pathways in pancreatic ductal adenocarcinomas with a bioinformatics approach.采用生物信息学方法分析胰腺导管腺癌中的分子通路。
Asian Pac J Cancer Prev. 2015;16(6):2561-7. doi: 10.7314/apjcp.2015.16.6.2561.
8
Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets.基于基因芯片数据集鉴定胰腺导管腺癌与正常胰腺组织中的差异表达基因。
Mol Med Rep. 2019 Aug;20(2):1901-1914. doi: 10.3892/mmr.2019.10414. Epub 2019 Jun 24.
9
Identification of hub genes and analysis of prognostic values in pancreatic ductal adenocarcinoma by integrated bioinformatics methods.通过综合生物信息学方法鉴定胰腺导管腺癌中的枢纽基因并分析其预后价值
Mol Biol Rep. 2018 Dec;45(6):1799-1807. doi: 10.1007/s11033-018-4325-2. Epub 2018 Sep 1.
10
Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.通过生物信息学分析鉴定与胰腺导管腺癌预后不良相关的新基因。
Biosci Rep. 2019 Aug 2;39(8). doi: 10.1042/BSR20190625. Print 2019 Aug 30.

引用本文的文献

1
Biomimetic Tumour Model Systems for Pancreatic Ductal Adenocarcinoma in Relation to Photodynamic Therapy.用于胰腺导管腺癌光动力治疗的仿生肿瘤模型系统
Int J Mol Sci. 2025 Jul 2;26(13):6388. doi: 10.3390/ijms26136388.
2
Application of integrin subunit genes in pancreatic cancer and the construction of a prognosis model.整合素亚基基因在胰腺癌中的应用及预后模型的构建
J Gastrointest Oncol. 2024 Oct 31;15(5):2286-2304. doi: 10.21037/jgo-24-612. Epub 2024 Oct 29.
3
Meningeal solitary fibrous tumor cell states phenocopy cerebral vascular development and homeostasis.

本文引用的文献

1
TNNT1 facilitates proliferation of breast cancer cells by promoting G/S phase transition.TNNT1 通过促进 G1/S 期转换促进乳腺癌细胞增殖。
Life Sci. 2018 Sep 1;208:161-166. doi: 10.1016/j.lfs.2018.07.034. Epub 2018 Jul 19.
2
Centromere protein U facilitates metastasis of ovarian cancer cells by targeting high mobility group box 2 expression.着丝粒蛋白U通过靶向高迁移率族蛋白盒2的表达促进卵巢癌细胞转移。
Am J Cancer Res. 2018 May 1;8(5):835-851. eCollection 2018.
3
Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer.
脑膜孤立性纤维瘤细胞状态模拟脑血管发育和稳态。
Neuro Oncol. 2025 Jan 12;27(1):155-166. doi: 10.1093/neuonc/noae172.
4
Emerging markers of cancer cachexia and their relationship to sarcopenia.癌症恶病质的新兴标志物及其与肌肉减少症的关系。
J Cancer Res Clin Oncol. 2023 Dec;149(19):17511-17527. doi: 10.1007/s00432-023-05465-9. Epub 2023 Oct 31.
5
The Performance Evaluation of The Random Forest Algorithm for A Gene Selection in Identifying Genes Associated with Resectable Pancreatic Cancer in Microarray Dataset: A Retrospective Study.用于在微阵列数据集中识别可切除胰腺癌相关基因的基因选择的随机森林算法性能评估:一项回顾性研究
Cell J. 2023 May 28;25(5):347-353. doi: 10.22074/cellj.2023.1971852.1156.
6
Revealing platelet-related subtypes and prognostic signature in pancreatic adenocarcinoma.揭示胰腺腺癌中的血小板相关亚型和预后特征。
BMC Med Genomics. 2023 May 17;16(1):106. doi: 10.1186/s12920-023-01530-x.
7
Analysis of dynamic molecular networks: the progression from colorectal adenoma to cancer.动态分子网络分析:从大肠腺瘤到癌症的进展
J Gastrointest Oncol. 2021 Dec;12(6):2823-2837. doi: 10.21037/jgo-21-674.
8
Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer.鉴定 DNA 甲基化驱动基因并构建列线图预测胰腺癌患者总生存期。
BMC Genomics. 2021 Nov 3;22(1):791. doi: 10.1186/s12864-021-08097-w.
9
COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma.COL4A1作为一种与恶性肿瘤临床特征相关的新型癌基因,预示着胶质瘤的预后不良。
Exp Ther Med. 2021 Nov;22(5):1224. doi: 10.3892/etm.2021.10658. Epub 2021 Aug 27.
10
Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma.胰腺癌中枢纽基因的鉴定及其新的诊断和预后意义
Cancer Biol Med. 2021 Aug 17;19(7):1029-46. doi: 10.20892/j.issn.2095-3941.2020.0516.
同源重组修复基因突变与胰腺癌对奥沙利铂反应之间的关联
Oncotarget. 2018 Apr 13;9(28):19817-19825. doi: 10.18632/oncotarget.24865.
4
DyNetViewer: a Cytoscape app for dynamic network construction, analysis and visualization.DyNetViewer:一个 Cytoscape 应用程序,用于动态网络构建、分析和可视化。
Bioinformatics. 2018 May 1;34(9):1597-1599. doi: 10.1093/bioinformatics/btx821.
5
Identification of a Gene Encoding Slow Skeletal Muscle Troponin T as a Novel Marker for Immortalization of Retinal Pigment Epithelial Cells.鉴定编码慢骨骼肌肌钙蛋白 T 的基因作为视网膜色素上皮细胞永生化的新型标志物。
Sci Rep. 2017 Aug 15;7(1):8163. doi: 10.1038/s41598-017-08014-w.
6
New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.晚期胰腺癌的新治疗方向:细胞周期抑制剂、基质调节剂和联合疗法。
Expert Opin Emerg Drugs. 2017 Sep;22(3):223-233. doi: 10.1080/14728214.2017.1362388. Epub 2017 Sep 3.
7
Centromere protein U is a potential target for gene therapy of human bladder cancer.着丝粒蛋白U是人类膀胱癌基因治疗的潜在靶点。
Oncol Rep. 2017 Aug;38(2):735-744. doi: 10.3892/or.2017.5769. Epub 2017 Jun 30.
8
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.GEPIA:一个用于癌症和正常基因表达谱分析及交互式分析的网络服务器。
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102. doi: 10.1093/nar/gkx247.
9
Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer.在一个多样性近交 F1 小鼠群体中绘制复杂性状图谱,确定了人类前列腺癌转移的种系修饰因子。
Cell Syst. 2017 Jan 25;4(1):31-45.e6. doi: 10.1016/j.cels.2016.10.018. Epub 2016 Dec 1.
10
miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.miRpower:一种利用2178例乳腺癌患者的表达数据来验证与生存相关的微小RNA的网络工具。
Breast Cancer Res Treat. 2016 Dec;160(3):439-446. doi: 10.1007/s10549-016-4013-7. Epub 2016 Oct 15.